New Key Statistics Module, Z-Score and F-Score
NAS:LYEL Key Ratios
| Market Cap $ M | 553.21 |
| Enterprise Value $ M | 77.81 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 0.84 |
| Price/Sales | 2,200.00 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -0.93 |
| Beneish M-Score | -67.8 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -0.31 |
| EV-to-EBITDA | -0.34 |
| PEG | -- |
| Shares Outstanding M | 254.94 |
| Net Margin (%) | -180,486.15 |
| Operating Margin % | -190,006.15 |
| Pre-tax Margin (%) | -180,486.15 |
| Quick Ratio | 16.07 |
| Current Ratio | 16.07 |
| ROA % (ttm) | -27.94 |
| ROE % (ttm) | -31.65 |
| ROIC % (ttm) | -100.18 |
| Dividend Yield % | -- |
| Altman Z-Score | 1.47 |
LYEL Number of Guru Trades
LYEL Volume of Guru Trades
Gurus Latest Trades with NAS:LYEL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:LYEL is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Lyell Immunopharma Inc Insider Transactions
No Available Data
News about NAS:LYEL
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers